The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS

Blood

Volumn 96, Issue 12, 2000, Pages 3932-3938

  Parker, Jane E ^a   Mufti, Ghulam J ^a   Rasool, Feyrooz ^a   Mijovic, Aleksandar ^a   Devereux, Stephen ^a   Pagliuca, Antonio ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HEMATOPOIESIS; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REFRACTORY ANEMIA; SCORING SYSTEM; STEM CELL;

EID: 0034551738     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.12.3932.h8003932_3932_3938     Document Type: Article

References (36)

1. Myelodysplastic syndromes: Natural history and features of prognostic importance
2. Hypothesis: Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome
3. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
4. Molecular thanatopsis: A discourse on the BCL2 family and cell death
5. Involvement of the bcl-2 gene in human follicular lymphoma
6. Bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells
7. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression
8. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy
9. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
10. Autonomous proliferation and bcl-2 expression involving haematopoietic cells in patients with myelodysplastic syndrome
11. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
12. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
13. 'Low risk' myelodysplastic syndrome (MDS) is associated with excessive apoptosis and an increased ratio of pro- versus anti-apoptotic Bcl-2 related proteins
14. Proposals for the classification of the myelodysplastic syndromes
15. International scoring system for evaluating prognosis in myelodysplastic syndromes
16. Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis
17. Incidence and role of apoptosis in myelodysplastic syndrome: Morphological and ultrastructural assessment
18. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes
19. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin
20. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia
21. Excessive proliferation matched by excessive apoptosis in myelodysplastic syndromes: The cause-effect relationship
22. Critical aspects in the analysis of apoptosis and necrosis
23. A common progenitor for human myeloid and lymphoid cells
24. Annexin-V and TUNEL use in monitoring the progression of apoptosis in plants
25. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl
26. A novel assay for apoptosis: Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labeled Annexin V
27. Is apoptosis a massive process in myelodysplastic syndromes?
28. High expression of phosphatidylserine (PS) in MDS, secondary AML (sAML) and normal progenitors: Comparison with primary AML (pAML)
29. Overexpression of tumor necrosis lactor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes
30. A role for tumour necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome
31. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes
32. In vitro and in vivo response to cyclosporin-A in myelodysplastic syndromes: Identification of a hypocellular subset responsive to immune suppression
33. Hematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vβ profiles
34. Prognostic value of the combined suicide level of granulocyte progenitors and the labeling index of precursors in preleukemic states and oligoblastic leukemias
35. Flow cytometric DNA content in myelodysplastic syndromes
36. DNA content and cell cycle analysis of bone marrow cells in myelodysplastic syndromes (MDS)